Decrease in the number of reported cases of zygomycosis among patients with diabetes mellitus: A hypothesis

Clinical Infectious Diseases

Volumn 44, Issue 8, 2007, Pages 1089-1090

  Kontoyiannis, Dimitrios P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; MEVINOLIN; SIMVASTATIN;

DEVELOPED COUNTRY; DIABETES MELLITUS; DRUG MECHANISM; DYSLIPIDEMIA; HUMAN; HYPOTHESIS; IN VITRO STUDY; IN VIVO STUDY; MUCORMYCOSIS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SHORT SURVEY; ARTICLE; PATHOPHYSIOLOGY;

DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ZYGOMYCOSIS;

EID: 33947536898     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/512817     Document Type: Short Survey

References (17)

1. Kontoyiannis DP, Lewis RE. Zygomycosis: update in epidemiology, pathogenesis and management. Infect Dis Clin North Am 2006; 20:581-607.
2. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in the era of Aspergillus-active antifungal therapy in a tertiary care cancer center: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191:1350-9.
3. Chamilos G, Lewis RE, Kontoyiannis DP. Multidrug-resistant endosymbiotic bacteria account for the emergence of zygomycosis: a hypothesis. Fungal Genet Biol 2006; 44:88-92.
4. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41:634-53.
5. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000; 13:236-301.
6. Saaddine JB, Calwell B, Gregg EW, et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med 2006; 144:465-74.
7. Centers for Disease Control and Prevention. National Diabetes Surveillance System. Diabetic ketoacidosis as first-listed diagnosis. 31 August 2005. Available at: http://www.cdc.gov/diabetes/statistics/dkafirst. Accessed 26 February 2007.
8. Centers for Disease Control and Prevention. National Diabetes Surveillance System. Prevalence of Diabetes. 6 October 2005. Available at: http://www.cdc.gov/diabetes/statistics/prev/national. Accessed 26 February 2007.
9. Rose LV, J Linz JE. Lovastatin triggers apoptosis-like cell death process in the fungus Mucor racemosus. Fungal Genet Biol 1998; 25:119-33.
10. Lukacs G, Papp T, Nyilasi I, Nagy E, Vagvolgyi C. Differentiation of Rhizomucor species on the basis of their different sensitivities to lovastatin. J Clin Microbiol 2004; 42:5400-2.
11. Galgoczy L, Papp T, Lukacs G, Leiter E, Pocsl I, Vagvolgyi C. Interactions between statins and Penicillium chrysogenum antifungal protein (PAF) to inhibit the germination of sporangiospores of different sensitive Zygomycetes. FEMS Microbiol Lett (in press).
12. Chamilos G, Lewis RE, Kontoyiannis DP. Lovastatin has significant activity against Zygomycetes and interacts synergistically with voriconazole. Antimicrob Agents Chemother 2006; 50:96-103.
13. Macreadie IG, Johnson G, Schlosser T, Macreadie PI. Growth inhibition of Candida species and Aspergillus fumigatus by statins. FEMS Microbiol Lett 2006; 262:9-13.
14. Miida T, Hirayama S, Nakamura Y. Cholesterol-independent effects of statins and new therapeutic strategies: ischemic stroke and dementia. J Atheroscler Thromb. 2004; 11:253-64.
15. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6:1399-402.
16. Kreisberg RA. Diabetic dyslipidemia. Am J Cardiol 1998; 82:67U-73U.
17. Solano MP, Goldberg RB. Management of dyslipidemia in diabetes. Cardiol Rev 2006; 14:125-35.